International trends in generics: the EU Posted 30/08/2010
Few studies have conducted an international price comparison of generic medicines as it is hard to access comparable data. A 2007 study by Prof. Dr. Steven Simoens examined national pricing policies in some EU countries and related them to generics prices (see Table 1).
Table 1: Generic medicine pricing policies and generic prices in selected countries in 2005 Country Generic medicines pricing policy Average factory gate prices for selected generics, 2005 (Euros) Belgium Generic medicines priced at least 30% lower than the original medicine 0.206 Denmark Generic medicines priced below the price level of original 0.104 Finland Free pricing system 0.220 France Generic medicines priced at least 40% lower than the original medicine 0.254 Germany Free pricing system 0.269 The Netherlands A system of maximum prices based on reference country prices 0.260 Norway A step-price system is in place that cuts the generic medicine price after a period of time 0.171 Sweden Regulated generic medicine prices system 0.123 United Kingdom Free pricing in a competitive environment 0.222 It is clear that another factor is affecting the price of generics, as the pricing policy does not directly govern the average price of generics. If the data is analysed from the perspective of maturity of the generics market, it can be seen that those countries in which generics have been established over a longer period of time pay less for their medicines (see Table 2). Table 2: Generic medicine prices compared to regulatory approach and level of development of generic medicine market in 2005 Generic medicine prices and regulatory approach towards generic medicine pricing Free market pricing Pricing regulation Country Average price level Country Average price level Finland Germany United Kingdom 0.237 Belgium Denmark France The Netherlands Norway Sweden 0.186 Generic medicine prices and level of development of generic medicine market Developing generic medicine market Mature generic medicine market Belgium Finland France Norway 0.213 Denmark Germany The Netherlands Sweden United Kingdom 0.196 The international price variation suggests that generic medicine companies do not set prices at a common European level, but adapt their price setting strategy to the regulatory environment surrounding generic medicines in each country. The generic medicine price level was lower in countries that regulate prices and in countries that have a mature generic medicine market. (see also International comparison of generic medicine prices) Reference Simoens S. International comparison of generic medicine prices. Curr Med Res Opin. 2007;23(11):2647–54.
Comments (0)
Generics News Research General
- Italy asked to comply with marketing rules for...Generics/News | Posted 03/02/2012
- Generics market to experience strong growth in...Generics/Research | Posted 03/02/2012
- Generic and biosimilar user fee recommendations...Generics/News | Posted 03/02/2012
- Watson expands in Asia with Ascent PharmahealthGenerics/News | Posted 27/01/2012
Biosimilars News Research General
- Amphastar and Watson launch biosimilar enoxaparinBiosimilars/News | Posted 03/02/2012
- Production of 24 biosimilars in Iran by 2012Biosimilars/News | Posted 03/02/2012
- Factors affecting market access of biosimilarsBiosimilars/Research | Posted 03/02/2012
- Sandoz starts phase III trials for biosimilar f...Biosimilars/News | Posted 27/01/2012




